THC-CBD Terpene Formulations for Autism Symptom Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for improved methods of treatment for autism spectrum disorder (ASD) that can effectively reduce symptoms and improve quality of life, as existing treatments have limited effectiveness and significant side effects.
Innovation Solution
A pharmaceutical composition comprising a Cannabinoid Profile with Tetrahydrocannabinol (THC) and Cannabidiol (CBD) at specific ratios, combined with a Terpene Profile including α-Pinene, Valencene, Eucalyptol, β-Caryophyllene, Myrcene, α-Bisabolol, and Pulegone, is administered to treat ASD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for autism spectrum disorder, then treatment is provided, but effectiveness is limited and side effects are significant
Solution Approach 1:
The patent applies composite materials by combining multiple cannabinoids (THC, CBD, CBG, CBC, CBN) with multiple terpenes (α-pinene, β-pinene, limonene, linalool, myrcene, eucalyptol, β-caryophyllene) in specific formulations. This composite approach creates a synergistic pharmaceutical composition that addresses autism spectrum disorder symptoms more effectively than single-compound treatments, while the balanced composition aims to reduce harmful side effects through the modulating effects of different constituents.
Solution Approach 2:
The patent employs parameter changes by systematically varying the ratios and concentrations of different cannabinoids and terpenes in multiple formulation embodiments. Specific ratios such as THC:CBD at 1:1 or 5:1, and varying terpene profiles with different abundance orders, are optimized to maximize therapeutic effectiveness while minimizing side effects. This parametric optimization allows tailoring the treatment to achieve the desired balance between efficacy and safety.
2Reliability
If medical marijuana is used for autism treatment, then therapeutic benefits are potential, but knowledge gap exists regarding utilization
Solution Approach 1:
The patent applies preliminary action by conducting comprehensive pre-clinical research and establishing detailed formulation protocols before clinical application. The patent provides extensive information about optimal ratios, terpene profiles, and administration methods that were previously unknown. This preliminary characterization of cannabinoid-terpene interactions and therapeutic windows fills the knowledge gap, enabling informed clinical utilization of medical marijuana for autism treatment.
Solution Approach 2:
The patent incorporates feedback mechanisms by monitoring and adjusting treatment parameters based on patient response. The detailed formulation specifications and ratio optimizations represent iterative refinement based on research feedback. This systematic approach to characterizing therapeutic effects and side effects creates a feedback loop that reduces the knowledge gap by translating empirical observations into actionable clinical guidelines.
Data Source
AI summary
The present disclosure provides for pharmaceutical compositions useful for treating autism spectrum disorder. The pharmaceutical compositions comprise particular THC:CBD ratios and terpene profiles, which have been demonstrated effective at treating cluster symptoms associated with autism spectrum disorder.